scispace - formally typeset
J

Jennifer S. Herrick

Researcher at University of Utah

Publications -  123
Citations -  6010

Jennifer S. Herrick is an academic researcher from University of Utah. The author has contributed to research in topics: Population & Colorectal cancer. The author has an hindex of 40, co-authored 104 publications receiving 5303 citations.

Papers
More filters
Journal ArticleDOI

The Role of Health Insurance in Patient Reported Satisfaction With Bladder Management in Neurogenic Lower Urinary Tract Dysfunction Due to Spinal Cord Injury

TL;DR: There is an association between insurance coverage and the type of bladder management used following SCI, where publicly insured patients are more likely to be managed with indwelling catheters and less likely to take bladder medication compared to those with private insurance.
Journal ArticleDOI

Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.

TL;DR: In this paper , the authors evaluated prevalence of primary prevention statin use by race and ethnicity according to 10-year ASCVD risk and found that the burden of atherosclerotic cardiovascular disease (ASCVD) in the US is higher among Black and Hispanic vs White adults.
Journal ArticleDOI

MicroRNA-messenger RNA interactions involving JAK-STAT signaling genes in colorectal cancer.

TL;DR: The results suggest that miRNAs facilitate this process to prevent uncontrolled growth from continuous JAK-STAT activation, and that positive beta coefficients may illustrate downstream effects of disrupted STAT activity, and subsequent miRNA upregulation.
Journal ArticleDOI

Maternal cardiovascular complications at the time of delivery and subsequent re-hospitalization in the USA, 2010-16.

TL;DR: The analyses suggest the rate of peripartum CV complications are increasing in the United States, which highlights the need for active efforts in research and prevention.
Journal ArticleDOI

The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl

TL;DR: In this article , the authors explored the population health impact of treating all US adults eligible for the REDUCE-IT with icosapent ethyl (IPE) trial, and estimated the number of ASCVD events and healthcare costs that could be prevented; and medication costs.